Grunenthal
The Grunenthal Group is a family-owned, science-based pharmaceutical company specialized in pain, gout and inflammation.
Based in Aachen, Germany, the company's ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and increase annual revenues to two billion euros. It has a strong presence in Europe and Latin America, and chief executive Gabriel Baertschi is seeking to grow the business from a geographic footprint point of view.
Latest Grunenthal News & Features
26 March 2024
2 August 2023
26 April 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze